Clinical trialNCT00517933CompletedPhase 3Interventional

Sildenafil Trial of Exercise Performance in Idiopathic Pulmonary Fibrosis

SponsorDuke UniversityEnrollment180Hypertension, PulmonaryPulmonary Fibrosis

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease that affects an individual's ability to breathe. This study will evaluate the effectiveness of sildenafil, a medication that increases blood flow to the lungs, at improving breathing function, exercise capacity, and quality of life in people with advanced IPF.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

David Zisman, MD
University of California, Los Angeles
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗
Fernando Martinez, MD
University of Michigan
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗
Ganesh Raghu, MD
University of Washington
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗
Gary Hunninghake, MD
University of Iowa
Study ChairKOL profile →
clinicaltrials.gov ↗
Herbert Reynolds, MD
National Heart, Lung, and Blood Institute (NHLBI)
Study Director
clinicaltrials.gov ↗
Imre Noth, MD
University of Chicago
Principal Investigator
clinicaltrials.gov ↗
James Loyd, MD
Vanderbilt University
Principal Investigator
clinicaltrials.gov ↗
Jay Ryu, MD
Mayo Clinic
Principal Investigator
clinicaltrials.gov ↗
Jesse Roman, MD
Emory University
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗
Joe Lasky, MD
Tulane University
Principal Investigator
clinicaltrials.gov ↗
Kevin Anstrom, PhD
Duke University
Principal Investigator
clinicaltrials.gov ↗
Kevin Brown, MD
National Jewish Health
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗
Lake D Morrison, MD
Duke University
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗
Rob Kaner, MD
Weill Medical College at Cornell University
Principal Investigator
clinicaltrials.gov ↗
Talmadge King, MD
University of California, San Francisco
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

13 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of Alabama - Birmingham
Birmingham, Alabama, United States
University of California - Los Angeles
Los Angeles, California, United States
University of California - San Francisco
San Francisco, California, United States
National Jewish Medical and Research Center
Denver, Colorado, United States
Emory University
Atlanta, Georgia, United States
University of Chicago
Chicago, Illinois, United States
Tulane University
New Orleans, Louisiana, United States
University of Michigan
Ann Arbor, Michigan, United States
Mayo Clinic
Rochester, Minnesota, United States
Weill Medical College of Cornell University
New York, New York, United States
Duke University Medical Center
Durham, North Carolina, United States
Vanderbilt University
Nashville, Tennessee, United States
University of Washington
Seattle, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Sildenafil →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Aug 2007
Primary completion: 31 May 2009
Completion: 31 Oct 2009
Last update posted: 24 Jun 2015
Registered enrollment: 180
Registry id: NCT00517933

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.